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Abstract
Activation of the serine-threonine kinase Akt promotes the survival and proliferation of various 
cancers. Hypoxia promotes the resistance of tumor cells to specific therapies. We therefore 
explored a possible link between hypoxia and Akt activity. We found that Akt was prolyl-
hydroxylated by the oxygen-dependent hydroxylase EglN1. The von Hippel–Lindau protein 
(pVHL) bound directly to hydroxylated Akt and inhibited Akt activity. In cells lacking oxygen or 
functional pVHL, Akt was activated to promote cell survival and tumorigenesis. We also identified 
cancer-associated Akt mutations that impair Akt hydroxylation and subsequent recognition by 
pVHL, thus leading to Akt hyperactivation. Our results show that microenvironmental changes, 
such as hypoxia, can affect tumor behaviors by altering Akt activation, which has a critical role in 
tumor growth and therapeutic resistance.
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Inactivation of the VHL tumor suppressor gene is the gatekeeper event in most hereditary 
[von Hippel–Lindau (VHL) disease] and sporadic clear-cell renal carcinomas (ccRCCs) (1–
3). Approved targeted therapies against advanced renal carcinomas include mechanistic 
target of rapamycin (mTOR) inhibitors (rapalogs) (4–6). Preclinical cancer models indicated 
that loss of VHL or phosphatase and tensin homolog (PTEN) increases rapalog sensitivity 
(7). Because Akt is frequently activated in VHL-defective renal carcinomas (8), we thus 
tested whether VHL protein (pVHL) might directly regulate Akt.
Cre-mediated deletion of VHL in conditional VHL-knockout mouse embryonic 
fibroblasts(MEFs) (9) increased Akt activity, as evidenced by increased phosphorylation at 
threonine 308 (pT308-Akt) and serine 473 (pS473-Akt) (Fig. 1A). Reintroducing pVHL in 
VHL-deficient renal carcinoma cells reduced pT308-Akt, and to a lesser extent pS473-Akt, 
in cells (Fig. 1B and fig. S1, A and B) and decreased Akt kinase activity in biochemical 
assays (fig. S1, C and D). Because phosphorylation of T308-Akt plays a more critical role in 
activating Akt than does phosphorylation of S473 (10), we focused on the regulation of the 
former by pVHL. (Single-letter abbreviations for the amino acid residues are as follows: A, 
Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; 
P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr. In the mutants, other amino 
acids were substituted at certain locations; for example, P125N indicates that proline at 
position 125 was replaced by asparagine.)
To test whether the regulation of Akt by pVHL in our system was hypoxia-inducible factor 
(HIF)–dependent, we depleted HIF1β (11) in renal carcinoma cells, which did not decrease 
pT308-Akt (fig. S2, A and B). Similarly, silencing HIF2α in 786-O cells or ectopically 
expressing a non-degradable HIF2α-PA (12, 13) in various cell lines did not alter pT308-Akt 
(fig. S2, C to F). Taken together, these results point to a HIF-independent link between 
pVHL and Akt activity.
Total Akt abundance was not affected by manipulating pVHL in different cell lines (Fig. 1, 
A and B). This left open the possibility that pVHL specifically polyubiquitylates phospho-
Akt. However, depletion of Cullin 2, which is required for pVHL-dependent ubiquitylation 
and leads to stabilized HIF2α (14) as expected, did not affect Akt phosphorylation (fig. 
S2G). These data suggest that pVHL suppresses Akt kinase activity in an E3 ligase–
independent manner.
Overexpressed pVHL bound to Akt1 and Akt2 but not to Akt3 (fig. S3, A to E). In contrast 
to the binding of HIF1α to pVHL (15, 16), Akt bound to wild type (WT) and most type 2 
but not type 1 pVHL mutants (fig. S3, F to I) (3, 16). Site-directed mutagenesis of critical 
residues within the hydroxyl-proline binding pocket of pVHL (13, 17) revealed that pVHL 
residues critical for binding to Akt1 and HIF1α partially overlap but are not identical (fig. 
S3, J to M). Likewise, WT and most type 2 but not type 1 pVHL mutants inhibited pT308-
Akt in 786-O cells (fig. S3N), suggesting that pVHL suppresses Akt through a direct 
physical association. Consistent with our findings in cell lines, pT308-Akt was increased in 
human VHL mutant ccRCC clinical samples relative to surrounding normal tissues (fig. S4, 
A to C).
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HIFα must be prolyl-hydroxylated by the egg-laying defective nine (EglN) oxygen-sensitive 
enzymes to bind pVHL (18–20). To test whether inhibition of Akt by pVHL is likewise 
regulated by oxygen, we exposed cells to 1% O2 or the EglN inhibitor 
dimethyloxaloylglycine (DMOG). Both treatments increased pT308-Akt in VHL-proficient 
but not VHL-deficient ccRCC cells (Fig. 1C and fig. S5A) in a HIF2α-independent manner 
(fig. S5B). Hypoxia and hypoxia-mimetics also disrupted the interaction of pVHL with Akt1 
(Fig. 1D and fig. S5, C to G).
Depletion of EglN1 (also termed PHD2), but not EglN2 or EglN3, increased Akt kinase 
activity in various cell lines (Fig. 2A and fig. S6, A to E). Reactive oxygen species (ROS) 
can destabilize PTEN and thereby activate Akt (21, 22). However, EglN1 inactivation 
minimally induced cellular ROS levels and did not down-regulate PTEN (Fig. 2A and fig. 
S6, F to I). Akt hyperactivation was reversed by reintroducing wild-type but not catalytic-
inactive EglN1 in EglN1−/− MEFs (Fig. 2B) or EglN1-depleted human embryonic kidney 
(HEK) 293 cells (fig. S6J). Furthermore, DMOG or hypoxia activated Akt in parental but 
not EglN1-depleted cells (Fig. 2C and fig. S6, K and L). Consistent with these findings, 
Akt1 bound to EglN1 but not EglN2 or EglN3, whereas both pVHL and EglN1 bound to 
Akt1 and Akt2 but not Akt3 (fig. S7, A to K). Moreover, the interaction of pVHL with Akt1 
was abolished in EglN1-depleted cells (fig. S8, A to C), and depleting EglN1 resulted in 
increased pT308-Akt only in VHL-WT cells but not VHL-deficient cells (Fig. 2D and fig. 
S8, D and E). Hence, EglN1 is required for pVHL to suppress Akt.
Both EglN1 and pVHL preferentially bound the activated form of Akt1 (E17K variant or 
myristoylated-Akt) (fig. S9, A to H) (23). Moreover, binding of EglN1 to Akt1 correlated 
with the appearance of pT308-Akt in cells stimulated with insulin or epidermal growth 
factor (EGF) (Fig. 2, E and F, and fig. S10, A to H). Conversely, blocking Akt 
phosphorylation decreased the interaction of Akt1 with EglN1 (fig. S10, I to K). To test 
whether Akt can be hydroxylated by EglN1, we identified hydroxylation of multiple Akt1 
prolyl-residues including Pro125, Pro313, Pro318, and Pro423 by means of liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) analysis (Fig. 3A and fig. S11, A 
to E). These prolyl-residues are highly conserved and can be divided into HIF oxygen-
dependent-degradation (ODD)–like sites (Pro318 and Pro423) (12, 13, 24) or Forkhead-Box-
O3 (FOXO3)–like sites (Pro125 and Pro313) (fig. S11F) (25). Mutating FOXO-like but not 
HIF-ODD–like sites reduced the interaction of Akt1 with pVHL (Fig. 3B), leading to 
increased pT308-Akt (Fig. 3C), arguing that these two residues are pivotal for the regulation 
of Akt by pVHL. Mutating FOXO-like sites to HIF-ODD motifs in Akt1 impaired its 
interaction with indicated type 2 pVHL mutants (fig. S12, A to F), again supporting that the 
pVHL residues used to bind hydroxylated HIFα and Akt are similar but not identical.
Mutations of Pro125 and Pro313 enhanced the interaction between Akt and its upstream 
kinase phosphoinositide-dependent kinase 1 (PDK1), leading to increased pT308-Akt that is 
insensitive to DMOG treatment (fig. S13, A to D). Moreover, hydroxylation-dependent 
recruitment of pVHL promoted the interaction of Akt1, but not Akt3, with the catalytic 
subunit of protein phosphatase 2A (PP2AC) (fig. S14, A to D) (26), which dephosphorylates 
pT308-Akt (27). The binding of PP2AC to Akt1, but not Akt3, was diminished in cells 
deficient in EglN1 or VHL or by mutating the Akt1 FOXO-like motifs (fig. S14, E to I). 
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Furthermore, recombinant pVHL promoted PP2A-mediated dephosphorylation of pT308-
Akt in vitro (fig. S14, J to L). Collectively, these data suggest that EglN1-induced 
hydroxylation of Akt suppresses Akt activation, in part, by triggering pVHL-mediated 
PP2A-induced dephosphorylation of pT308-Akt (fig. S14M).
To test whether prolyl-hydroxylation might alter the recognition of Akt1 by pVHL, we 
performed in vitro binding assays with biotinylated Akt1-derived peptides. Peptides 
spanning the Akt1 FOXO-like sites bound to pVHL in a hydroxylation-dependent manner 
(Fig. 3, D and E). Furthermore, hydroxylated Akt1 peptides bound to WT and most type 2 
but not type 1 pVHL mutants (Fig. 3E and fig. S15, A to E). Synthetic hydroxyl-peptides 
derived from HIF1α or Akt1 competed with one another for binding to pVHL (fig. S15, F 
and G). To study the Akt1 FOXO-like hydroxylation sites in cells, we generated and 
validated antibodies to Akt-Pro125-OH or Akt-Pro313-OH (fig. S16, A to F). In agreement 
with EglN1 as the major upstream hydroxylase for Akt, recognition of Akt1 by the Akt-
Pro313-OH antibody was diminished in EglN1-depleted cells and by hypoxic conditions 
(Fig. 3, F and G, and fig. S16, G to I). In multiple cell lines, Akt1 hydroxylation was 
triggered by growth factors (fig. S16, J to N). Using in vitro hydroxylation assays (fig. S17, 
A to C) (25, 28) coupled with MS analysis, we identified both Pro125 and Pro313 residues as 
hydroxylation sites by EglN1 (Fig. 3H and fig. S17, D to K).
Given that aberrant Akt activation can alter cell survival and metabolism to favor 
tumorigenesis, we evaluated whether hydroxylation of Akt modulates Akt-oncogenic 
signaling. Reintroducing the FOXO-like hydroxylation-deficient mutants (P125A and/or 
P313A) of Akt1, but not the corresponding Akt3 variants, into DLD1-AKT1−/−/AKT2−/− 
cells (denoted AKT1/2−/−) led to increased pT308-Akt as compared with AKT1/2−/− cells 
expressing wild-type Akt (Fig. 4, A to C, and fig. S18, A to G). Moreover, P125A and/or 
P313A of Akt1, but not the corresponding mutation in Akt3, promoted colony formation and 
anchorage-independent growth in vitro, as well as enhanced tumor formation in vivo relative 
to wild-type Akt (Fig. 4, D to I, and fig. S18, H to R).
We also identified two cancer-associated Akt mutations, Akt1-G311D and Akt2-P127N 
(www.cbioportal.org) (Fig. 4J) (29). The corresponding Akt mutants displayed reduced Akt 
hydroxylation, associated with reduced interaction with pVHL and PP2AC (Fig. 4K and fig. 
S19, A to E), leading to increased pT308-Akt (Fig. 4L). Biologically, reintroducing either 
P125N or G311D mutant of Akt1 or P127N-Akt2 in AKT1/2−/− cells led to sustained 
activation of Akt oncogenic signaling (fig. S19, F to I), as well as increased oncogenic 
functions (Fig. 4, M and N, and fig. S19, J to O). These results indicate that these cancer-
associated mutations in Akt exhibit increased oncogenic activity because of loss of proline-
hydroxylation–dependent inhibition of Akt by pVHL (fig. S19P).
Therefore, our studies revealed that hypoxia and deficiencies in the VHL/EGLN tumor-
suppressive pathway, in a HIF-independent and prolyl hydroxylation–dependent manner, 
lead to aberrant Akt activation, which in many models promotes apoptotic resistance. 
Conceivably, hypoxia-induced Akt activation promotes the survival of stem cells within 
hypoxia niches, regenerating cells within ischemic tissues and wounds, and cancer cells 
within hypoxic tumors. In a VHL-deficient ccRCC setting, accumulation of HIFα and 
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activated Akt are likely to be integrated to promote renal carcinogenesis and metastasis (30). 
This view provides further support for targeting phosphatidylinositol 3-kinase and/or Akt to 
treat pVHL-defective kidney cancers specifically and as a way to chemosensitize hypoxic 
tumors generally.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank B. North, L. Wan, and other Wei laboratory members for critical reading of the manuscript; W. Yu for his 
critical help in providing the triple mutant form of VHL to analyze the critical amino acids in proline-hydroxylation 
binding pocket of VHL that mediates its interaction with hydroxylated Akt1; as well as members of Kaelin, Zhang, 
Toker, and Cheng laboratories for helpful discussions. J.G. is an NRSA T32 trainee and supported by 
5T32HL007893-17. W.W. is an ACS research scholar. This work was supported in part by NIH grants (W.W., 
GM094777; W.W. and A.T., CA177910; and J.A., 1S10OD010612, 5P01CA120964, and 5P30CA006516).
REFERENCES AND NOTES
1. Chen F, et al. Hum. Mutat. 1995; 5:66–75. [PubMed: 7728151] 
2. Gossage L, Eisen T, Maher ER. Nat. Rev. Cancer. 2015; 15:55–64. [PubMed: 25533676] 
3. Kim WY, Kaelin WG. J. Clin. Oncol. 2004; 22:4991–5004. [PubMed: 15611513] 
4. Thomas GV, et al. Nat. Med. 2006; 12:122–127. [PubMed: 16341243] 
5. Hudes G, et al. N. Engl. J. Med. 2007; 356:2271–2281. [PubMed: 17538086] 
6. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. Cancer Cell. 2003; 4:147–158. 
[PubMed: 12957289] 
7. Laplante M, Sabatini DM. Cell. 2012; 149:274–293. [PubMed: 22500797] 
8. Hager M, et al. J. Cell. Mol. Med. 2009; 13(8B):2181–2188. [PubMed: 18774962] 
9. Young AP, et al. Nat. Cell Biol. 2008; 10:361–369. [PubMed: 18297059] 
10. Aoki M, Batista O, Bellacosa A, Tsichlis P, Vogt PK. Proc. Natl. Acad. Sci. U.S.A. 1998; 
95:14950–14955. [PubMed: 9843996] 
11. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC. Nature. 1997; 386:403–407. 
[PubMed: 9121557] 
12. Maxwell PH, et al. Nature. 1999; 399:271–275. [PubMed: 10353251] 
13. Min JH, et al. Science. 2002; 296:1886–1889. [PubMed: 12004076] 
14. Lonergan KM, et al. Mol. Cell. Biol. 1998; 18:732–741. [PubMed: 9447969] 
15. Ohh M, et al. Nat. Cell Biol. 2000; 2:423–427. [PubMed: 10878807] 
16. Li L, et al. Mol. Cell. Biol. 2007; 27:5381–5392. [PubMed: 17526729] 
17. Hon WC, et al. Nature. 2002; 417:975–978. [PubMed: 12050673] 
18. Ivan M, et al. Science. 2001; 292:464–468. [PubMed: 11292862] 
19. Jaakkola P, et al. Science. 2001; 292:468–472. [PubMed: 11292861] 
20. Yu F, White SB, Zhao Q, Lee FS. Proc. Natl. Acad. Sci. U.S.A. 2001; 98:9630–9635. [PubMed: 
11504942] 
21. Zhang H, et al. Cancer Cell. 2007; 11:407–420. [PubMed: 17482131] 
22. Huang D, et al. Cell Reports. 2014; 8:1930–1942. [PubMed: 25242319] 
23. Carpten JD, et al. Nature. 2007; 448:439–444. [PubMed: 17611497] 
24. Luo W, et al. Cell. 2011; 145:732–744. [PubMed: 21620138] 
25. Zheng X, et al. Genes Dev. 2014; 28:1429–1444. [PubMed: 24990963] 
26. Li J, et al. Nature. 2002; 420:716–717. [PubMed: 12478304] 
Guo et al. Page 5





















27. Millward TA, Zolnierowicz S, Hemmings BA. Trends Biochem. Sci. 1999; 24:186–191. [PubMed: 
10322434] 
28. Zhang JH, et al. Anal. Biochem. 1999; 271:137–142. [PubMed: 10419628] 
29. Cerami E, et al. Cancer Discov. 2012; 2:401–404. [PubMed: 22588877] 
30. Gan B, et al. Cancer Cell. 2010; 18:472–484. [PubMed: 21075312] 
Guo et al. Page 6





















Fig. 1. pVHL suppresses Akt phosphorylation
(A) Immunoblot (IB) analysis of whole-cell lysates (WCL) derived from VHLf/f MEFs 
infected with Cre or control (EV) lentivirus. (B) IB analysis of WCL derived from RCC4 or 
786-O cells infected with EV or VHL retrovirus. (C and D) 786-O cells were engineered via 
retroviral infection to stably express pVHL and harvested for hemagglutinin-
immunoprecipitation (HA-IP) or IB analysis after culturing under normoxia or hypoxia (1% 
O2) condition for 16 hours.
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Fig. 2. EglN1 mediates the inhibition of Akt by pVHL
(A and C) IB analysis of WCL derived from HEK293 cells (A) infected with different short 
hairpin RNA (shRNA) lentiviruses, and then (C) treated with or without DMOG (200 µM) 
for 12 hours before harvesting. (B) IB analysis of EglN1−/− MEFs infected with retroviruses 
encoding WT or catalytic-inactive (P317R)mutant form of EglN1. (D) IB analysis of WCL 
derived from786-O-pVHL and EV cells lentivirally infected with Scramble (sh-Src) or 
EglN1 shRNAs. (E and F) IB analysis of IP and WCL derived from HEK293 cells 
transfected with indicated constructs. (E) The cells were serum-starved for 24 hours and then 
stimulated with insulin (0.1 µM) before harvesting. The relative intensities of EglN1 and 
pVHL immunoprecipitated by Akt1 in (E) are quantified in (F).
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Fig. 3. EglN1 hydroxylates Akt1 at the Pro125 and Pro313 residues to trigger Akt1 interaction 
with pVHL
(A) A schematic illustration of Akt1 domain structures with four putative prolyl-
hydroxylation residues identified by means of LC-MS/MS analysis. (B and C) IB analysis of 
co-immunoprecipitation and WCL derived from HEK293 cells transfected with Flag-pVHL 
and indicated HA-Akt1 constructs. (D) A schematic representation of the various 
biotinylated synthetic peptides used in this study. FOXO-like and HIF-ODD–like motifs 
were labeled in red and green, respectively. (E) Indicated peptides as denoted in (D) were 
incubated with WCL derived from HEK293 cells transfected with indicated constructs, and 
precipitated with streptavidin. (F) IB analysis of WCL derived from HEK293 cells 
transfected with indicated constructs. Where indicated, hypoxia mimetic reagents were used 
before harvesting for IB analysis. (G) IB analysis of WCL derived from WT or EglN1−/− 
MEFs infected with a retrovirus encoding Flag-tagged WT-EglN1. (H) In vitro 
hydroxylation assays with recombinant His-EglN1 and various Akt1 peptides were analyzed 
by means of dot immunoblot.
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Fig. 4. Disruption of Akt proline-hydroxylation events leads to a sustained Akt kinase activation 
and increased colony formation and tumor growth
(A to C) IB analysis of WCL derived fromDLD1-AKT1/2−/− cells (A) infected with 
lentiviruses encoding WT- or P125/313A-Akt1. (B) Cells were deprived of serum for 24 
hours followed by stimulation with insulin (0.1 µM), and relative pT308-Akt intensity was 
quantified in (C). (D to G) Colony formation (D) and soft agar (F) assays were performed 
with DLD1-AKT1/2−/− cells generated in (A), and were quantified in (E) and (G) (mean ± 
SD, n = 3 wells per group). *P < 0.05 (Student’s t test). (H and I) Mouse xenograft 
experiments were performed with the cells generated in (A). Tumor growth curve (H) and 
tumor weight (I) were calculated (mean ± SD, n = 6 mice per group). *P < 0.05 (one-way 
analysis of variance test). (J) A schematic representation of cancer patient-associated Akt 
mutations. (K and L) Glutathione S-transferase pull-down and IP analysis of WCL derived 
from HEK293 cells transfected with indicated constructs. (M and N) Relative colony 
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numbers were quantified for colony formation (M) and soft agar (N) assays (mean ± SD, n = 
3 wells per group). *P < 0.05, **P < 0.01 (Student’s t test).
Guo et al. Page 11
Science. Author manuscript; available in PMC 2017 February 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
